Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
Open-label, Uncontrolled, Prospective Long-term Observation of Ventavis Inhalation Therapy in the Treatment of Patients With Primary Pulmonary Hypertension up to 4 Years
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Brest, France, F-29609
-
Clamart Cedex, France, 92141
-
Lille, France, 59037
-
Lyon Cedex 03, France, 69394
-
Pessac, France, 33604
-
Reims, France, 51092
-
Strasbourg, France, 67091
-
Vandoeuvre les Nancy Cedex, France, 54500
-
-
-
-
-
Berlin, Germany, 12200
-
Berlin, Germany, 13353
-
Hamburg, Germany, 20246
-
-
Baden-Württemberg
-
Donaueschingen, Baden-Württemberg, Germany, 78166
-
Heidelberg, Baden-Württemberg, Germany, 69120
-
Heidelberg, Baden-Württemberg, Germany, 69126
-
Löwenstein, Baden-Württemberg, Germany, 74245
-
-
Bayern
-
Erlangen, Bayern, Germany, 91054
-
München, Bayern, Germany, 80336
-
München, Bayern, Germany, 81377
-
Regensburg, Bayern, Germany, 93053
-
-
Hessen
-
Gießen, Hessen, Germany, 35392
-
-
Nordrhein-Westfalen
-
Bonn, Nordrhein-Westfalen, Germany, 53105
-
Essen, Nordrhein-Westfalen, Germany, 45147
-
Köln, Nordrhein-Westfalen, Germany, 50924
-
Mönchengladbach, Nordrhein-Westfalen, Germany, 41069
-
Wuppertal, Nordrhein-Westfalen, Germany, 42283
-
-
Saarland
-
Homburg/Saar, Saarland, Germany, 66421
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01307
-
Leipzig, Sachsen, Germany, 04103
-
-
Thüringen
-
Erfurt, Thüringen, Germany, 99089
-
-
-
-
-
Bologna, Italy, 40138
-
Pavia, Italy, 27100
-
Pisa, Italy, 56100
-
Roma, Italy, 00161
-
-
-
-
-
Coimbra, Portugal, 3000-075
-
Lisboa, Portugal, 1150-291
-
-
-
-
-
Barcelona, Spain, 08036
-
Barcelona, Spain, 08035
-
Córdoba, Spain, 14004
-
Madrid, Spain, 28041
-
-
-
-
-
Glasgow, United Kingdom, G11 6NT
-
London, United Kingdom, NW3 2PF
-
Newcastle upon Tyne, United Kingdom, NE7 7DN
-
Sheffield, United Kingdom, S10 2JF
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The treating physician has chosen Ventavis as a suitable long-term treatment for the patient
- Patient with primary pulmonary hypertension (i.e. Idiopathic Pulmonary Arterial Hypertension or Familial Pulmonary Arterial Hypertension) and classified as NYHA functional class III (NYHA = New York Heart Association)
- No prior treatment with Ventavis or other active treatments for primary pulmonary hypertension within 6 weeks of date of study inclusion (unless otherwise advised by Bayer Schering Pharma)
Exclusion Criteria:
- Any condition that prevents participation in the study, including pregnancy and other contraindications for Ventavis treatment (as listed in the current Ventavis Summary of Product Characteristics and patient package insert)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1
|
The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser).
Dosing should follow the recommendations of the current package leaflet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary efficacy variable is 6-minute walking distance. Focus will lay on the individual changes (in meters) at Month 3 (after inhalation) compared to the value measured at baseline.
Time Frame: Month 3 Visit
|
Month 3 Visit
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relative change in the 6-minutes walking distance (%), as compared to baseline (BL): clinical improvement is defined as an increase of at least 10% vs BL; clinically significant deterioration is defined as a decrease of at least 30% vs BL.
Time Frame: all scheduled visits (Study period is min. 2 years and max. 4 years)
|
all scheduled visits (Study period is min. 2 years and max. 4 years)
|
|
|
Changes in the NYHA class (to determine the patients' clinical conditions) vs. baseline will be classified into: improved, unchanged and deteriorated. Improvement is a negative difference; deterioration is a NYHA class increase from baseline.
Time Frame: all scheduled visits (Study period is min. 2 years and max. 4 years)
|
all scheduled visits (Study period is min. 2 years and max. 4 years)
|
|
|
Mortality, defined as all-cause mortality, will be assessed for all patients included in this study.
Time Frame: all scheduled visits (Study period is min. 2 years and max. 4 years)
|
all scheduled visits (Study period is min. 2 years and max. 4 years)
|
|
|
The safety and tolerability of Ventavis will be assessed by an examination of the adverse event data collected in this study.
Time Frame: all scheduled visits (Study period is min. 2 years and max. 4 years)
|
all scheduled visits (Study period is min. 2 years and max. 4 years)
|
|
|
Other safety variable
Time Frame: At all scheduled visits (Study period is min. 2 years and max. 4 years)
|
Weight, vital signs, findings in PPH-related signs and symptoms, hospitalization because of PPH, incidence of heart and/or lung transplantation
|
At all scheduled visits (Study period is min. 2 years and max. 4 years)
|
|
Other safety variables (optional assessment)
Time Frame: At all scheduled visits (Study period is min. 2 years and max. 4 years)
|
Chest x-ray, electrocardiogram, findings of heart catheter test, findings of pulmonary function tests, findings of blood gas analyses
|
At all scheduled visits (Study period is min. 2 years and max. 4 years)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 91430
- 308120 (Other Identifier: Company internal)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.